© 2022 by Elsevier GmbH
Bitte nutzen Sie das untenstehende Formular um uns Kritik, Fragen oder Anregungen zukommen zu lassen.
Willkommen
Mehr InformationenBB09a-9783437229640.10001-8
10.1016/BB09a-9783437229640.10001-8
B09a-9783437229640
###
Chronische lymphatische Leukämie
Einleitung
Diagnostik
-
Fluoreszenz-in-situ-Hybridisierung (FISH)
-
TP53-Mutationsanalyse
-
IGHV-Mutationsstatus
-
Karyotypisierung
Therapie
Generelle Aspekte vor Therapieeinleitung
Empfehlungen zur Erstlinientherapie
Ibrutinib
Acalabrutinib
Venetoclax plus Obinutuzumab
Empfehlungen zur Rezidivtherapie
Venetoclax plus Rituximab
Ibrutinib
Acalabrutinib
Kardiovaskuläre Toxizität von BTK-Inhibitoren
Fazit für die Praxis
Autorenadressen
Literatur
1.
Condoluci A, Terzi di Bergamo L, Langerbeins P, et al.: International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood 135(21) (2020) 1859–1869.
2.
Bomben R, Rossi FM, Vit F, et al.: TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. Clin Cancer Res 27(20) (2021) 5566–5575.
3.
Kittai AS, Miller CR, Goldstein D, et al.: The impact of increasing karyotypic complexity and evolution on survival in CLL patients treated with ibrutinib. Blood 138(23) (2021) 2372–2382.
4.
The international CLL-IPI working group: An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17(6) (2016) 779–790.
5.
Langerbeins P, Zhang C, Robrecht S, et al.: The CLL12 trial: Ibrutinib versus placebo in treatment-naïve, early stage chronic lymphocytic leukemia. Blood Nov 10 (2021) blood.2021010845.
6.
Burger JA, Tedeschi A, Barr PM, et al.: Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New Engl J Med 373(25) (2015) 2425–2437.
7.
Woyach JA, Ruppert AS, Heerema NA, et al.: Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New Engl J Med 379(26) (2018) 2517–2528.
8.
Moreno C, Greil R, Demirkan F, et al.: Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(1) (2019) 43–56.
9.
Shanafelt TD, Wang XV, Kay NE, et al.: Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. New Engl J Med 381(5) (2019) 432–443.
10.
Wang V, Hanson CA, Tschumper R, et al.: Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib. Blood 138(26) (2021) 2810–2827. doi: 10.1182/blood.2020010146. Epub ahead of print. PMID: 34407545.
11.
Sivina M, Kim E, Wierda WG, et al.: Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. Blood 138(24) (2021) 2589–2592. Doi: 10.1182/blood.2021012315. PMID: 34521099.
12.
Sharman JP, Egyed M, Jurczak W, et al.: Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet (London, England) 395(10232) (2020) 1278–1291.
13.
Ghia P, Pluta A, Wach M, et al.: ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 38(25) (2020) 2849–2861.
14.
Byrd JC, Woyach JA, Furman RR, et al.: Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood 137(24) (2021) 3327–3338.
15.
Fischer K, Al-Sawaf O, Bahlo J, et al.: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. New Engl J Med 380(23) (2019) 2225–2236.
16.
Al-Sawaf O, Zhang C, Lu T, et al.: Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J Clin Oncol 2021: Jco2101181.
17.
Kater AP, Wu JQ, Kipps T, et al.: Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol 38(34) (2020) 4042–4054.
18.
Ma S, Seymour JF, Brander DM, et al.: Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood 138(10) (2021) 836–846.
19.
Byrd JC, Brown JR, O'Brien S, et al.: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New Eng J Med 371(3) (2014) 213–223.
20.
Chanan-Khan A, Cramer P, Demirkan F, et al.: Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 17(2) (2016) 200–211.
21.
Byrd JC, Hillmen P, Ghia P, et al.: Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol 39(31) (2021) 3441–3452.
22.
Rogers KA, Thompson PA, Allan JN, et al.: Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica 106(9) (2021) 2364–2373.
23.
Brown JR, Moslehi J, Ewer MS, et al.: Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Brit J Haematol 184(4) (2019) 558–569.
24.
Brown JR, Byrd JC, Ghia P, et al.: Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica 2021 Sep 30. Doi: 103324/haematol.2021.278901. Epub ahead of print. PMID: 34587719.